Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.66 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.59 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.59 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.51 |
| ▸ | TBXAS1 | P24557 | 5/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25575670 | 0.98 | MAPT (0.69) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| Iocanlidic Acid SCHEMBL290025 | 0.98 | MAPT (0.69) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| SCHEMBL9860436 | 0.98 | MAPT (0.69) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| SCHEMBL2835656 | 0.98 | MAPT (0.69) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| SCHEMBL452845 | 0.94 | SMN1; SMN2 (0.67) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| Iocanlidic Acid SCHEMBL27870026 | 0.91 | MAPT (0.61) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| SCHEMBL7065645 | 0.89 | MAPT (0.79) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| SCHEMBL29256339 | 0.89 | MAPT (0.58) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| SCHEMBL6015502 | 0.88 | MAPT (0.57) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| SCHEMBL9671779 | 0.87 | MAPT (0.83) | MAPTRXFP1HDAC3MAPK1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250127938-A1 | THERAGNOSTIC FOLATE CONJUGATES | MERCK PATENT GMBH (DE) | 2025-04-24 | — | — | US | disclosed |
| US-20250127938-A1 | THERAGNOSTIC FOLATE CONJUGATES | MERCK PATENT GMBH (DE) | 2025-04-24 | — | — | US | disclosed |
| US-20250108138-A1 | THERAGNOSTIC FOLATE CONJUGATES | MERCK PATENT GMBH (DE) | 2025-04-03 | — | — | US | disclosed |
| CN-119735606-A | Preparation method of gem-bis (boron group) -containing cyclopropane compound | 南京工业大学 | 2025-04-01 | — | — | CN | disclosed |
| EP-4472677-A1 | THERAGNOSTIC FOLATE CONJUGATES | Merck Patent GmbH (DE) | 2024-12-11 | — | — | EP | disclosed |
| EP-4472677-A1 | THERAGNOSTIC FOLATE CONJUGATES | Merck Patent GmbH (DE) | 2024-12-11 | — | — | EP | disclosed |
| CN-118660723-A | Therapeutic diagnostic folate conjugates | 默克专利股份有限公司 | 2024-09-17 | — | — | CN | disclosed |
| CN-118647412-A | Therapeutic diagnostic folate conjugates | 默克专利股份有限公司 | 2024-09-13 | — | — | CN | disclosed |
| US-11874278-B2 | Reagents for directed biomarker signal amplification | SIRIGEN II LIMITED (GB) | 2024-01-16 | — | — | US | disclosed |
| US-20230273215-A1 | Novel Reagents for Directed Biomarker Signal Amplification | SIRIGEN, INC. | 2023-08-31 | — | — | US | disclosed |
| US-7674397-B2 | Reactive mesogenic charge transport compounds | Merck Patent Gesellschaff mit beschrankter Haftung (DE) | 2010-03-09 | — | — | US | disclosed |
| US-7674397-B2 | Reactive mesogenic charge transport compounds | Merck Patent Gesellschaff mit beschrankter Haftung (DE) | 2010-03-09 | — | — | US | disclosed |
| CN-101570533-A | Reactive mesogenic charge transport compounds | MERCK PATENT GMBH (DE) | 2009-11-04 | — | — | CN | disclosed |
| US-20090243469-A1 | ORGANIC ELECTROLUMINESCENT ELEMENT AND DISPLAY DEVICE INCLUDING THE SAME | FUJI XEROX CO., LTD. (JP) | 2009-10-01 | — | — | US | disclosed |
| EP-1903036-A1 | Reactive mesogenic charge transport compounds containing at least two thiophene groups | Merck Patent GmbH (DE) | 2008-03-26 | — | — | EP | disclosed |
| EP-1903036-A1 | Reactive mesogenic charge transport compounds containing at least two thiophene groups | Merck Patent GmbH (DE) | 2008-03-26 | — | — | EP | disclosed |
| CN-1922167-A | Reactive mesogenic charge transport compounds | MERCK PATENT GMBH (DE) | 2007-02-28 | — | — | CN | disclosed |
| EP-1725541-A2 | REACTIVE MESOGENIC CHARGE TRANSPORT COMPOUNDS CONTAINING AT LEAST TWO THIOPHENE GROUPS | MERCK PATENT GmbH (DE) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005080369-A2 | REACTIVE MESOGENIC CHARGE TRANSPORT COMPOUNDS CONTAINING AT LEAST TWO THIOPHENE GROUPS | MERCK PATENT GMBH (DE) | 2005-09-01 | — | — | WO | disclosed |
| US-20050184274-A1 | Reactive mesogenic charge transport compounds | MERCK PATENT GMBH (DE) | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250108138-A1 | THERAGNOSTIC FOLATE CONJUGATES | FOLR1, MTHFD1, MTHFD2 | MAPT 531/4885RXFP1 2275/4885HDAC3 4112/4885 |
| US-11874278-B2 | Reagents for directed biomarker signal amplification | RNGTT, CAPG, CA14 | MAPT 3033/4885RXFP1 3107/4885HDAC3 4583/4885 |
| US-20250127938-A1 | THERAGNOSTIC FOLATE CONJUGATES | FOLR1, FOLR2, DHFR | MAPT 632/4885RXFP1 2356/4885HDAC3 4016/4885 |
| US-20230273215-A1 | Novel Reagents for Directed Biomarker Signal Amplification | RNGTT, CAPG, CD2BP2 | MAPT 3230/4885RXFP1 2858/4885HDAC3 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.